|
|
CAF24a |
|
Vaxjo ID |
351 |
|
Vaccine Adjuvant Name |
CAF24a |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
CAF24a is a nanoemulsion adjuvant engineered from the active components of a liposomal adjuvant known as CAF09.[1] It is designed to stimulate cytotoxic T-lymphocyte (CTL) responses, and immune profile: Th1 |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
CAF24a is a nanoemulsion containing biodegradable squalane, the cationic lipid dimethyldioctadecylammonium (DDA) bromide, a synthetic monomycoloyl glycerol analog, polyinosinic:polycytidylic acid (Poly(I:C)), and zwitterionic distearoylphosphoethanolamine.[1] The model antigen used in the study was chicken egg ovalbumin (OVA) |
|
Structure |
nanoemulsion |
|
Function |
CAF24a is a promising adjuvant for inducing cytotoxic T-lymphocyte (CTL) responses after subcutaneous (s.c.) and intramuscular (i.m.) immunization.[1] It is designed for vaccines against pathogens where CTL responses are necessary for preventing infection. |
|
Safety |
The article does not explicitly detail the safety profile of CAF24a, but it is based on the components of CAF09 and utilizes biodegradable squalane. |
| Related Vaccine(s) |
|
| References |
Schmidt et al., 2018: Schmidt ST, Pedersen GK, Neustrup MA, Korsholm KS, Rades T, Andersen P, Foged C, Christensen D. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). Frontiers in immunology. 2018; 9; 898. [PubMed: 29760705].
|
|
